PALO ALTO, Calif., Feb. 9 /PRNewswire-FirstCall/ -- Telik, Inc. announced that its year-end conference call and webcast will be held on Thursday, February 22, 2007 at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) following the release earlier that day of the company’s financial results for the fourth quarter and year ended December 31, 2006.
The conference call will be accessible via Telik’s website at www.telik.com or by telephone at 800-230-1085 or 612-234-9960. An archive of the conference call will be available on the Telik website or by telephone at 800-475-6701 or 320-365-3844, access code 863181. The archive will be available from approximately 8:30 p.m. Eastern time on February 22 through March 1, 2007.
Telik, Inc. of Palo Alto, CA is a biopharmaceutical company focused on discovering, developing and commercializing novel small molecule drugs to treat serious diseases. The company’s most advanced drug development candidate is TELCYTA(R), a tumor-activated small molecule product candidate in clinical development for the treatment of advanced ovarian cancer and non-small cell lung cancer. A second development candidate, TELINTRA(TM), is in clinical development in myelodysplastic syndrome. Telik’s product candidates were discovered using its proprietary drug discovery technology, TRAP(TM), which enables the rapid and efficient discovery of small molecule drug candidates. Additional information is available at www.telik.com.
Telik, Inc.
CONTACT: Carol D. DeGuzman, Senior Director, Corporate Communications ofTelik, Inc., +1-650-845-7728, or cdeguzman@telik.com
Web site: http://www.telik.com//
